How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, gender, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Roxadustat for treating anaemia in chronic kidney disease

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about roxadustat

Marketing authorisation indication

2.1 Roxadustat (Evrenzo, Astellas Pharma) 'is indicated for treatment of adult patients with symptomatic anaemia associated with chronic kidney disease (CKD).'

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics.

Price

2.3 The list prices of roxadustat are:

  • £59.24 per 12‑tablet pack, each tablet contains 20 mg of roxadustat (excluding VAT; BNF online, accessed December 2021)

  • £148.11 per 12‑tablet pack, each tablet contains 50 mg of roxadustat (excluding VAT; BNF online, accessed December 2021)

  • £207.35 per 12‑tablet pack, each tablet contains 70 mg of roxadustat (excluding VAT; BNF online, accessed December 2021)

  • £296.21 per 12‑tablet pack, each tablet contains 100 mg of roxadustat (excluding VAT; BNF online, accessed December 2021)

  • £444.32 per 12‑tablet pack, each tablet contains 150 mg of roxadustat (excluding VAT; BNF online, accessed December 2021).

The company has a commercial arrangement, which would have applied if the technology had been recommended.